Next-Generation Biomanufacturing Market
Number of pages: 100 | Report Format: PDF | Published date: May 08, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 19.02 billion |
|
Revenue Forecast in 2031 |
US$ 34.81 billion |
|
CAGR |
6.9% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Workflow Type, Application, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global next-generation biomanufacturing market was valued at US$ 19.02 billion in 2022 and is expected to register a revenue CAGR of 6.9% to reach US$ 34.81 billion by 2031.
Next-Generation Biomanufacturing Market Fundamentals
Next-generation biomanufacturing is the application of advanced technologies and innovative processes to produce biologics, complex molecules produced by living cells that treat a wide range of diseases. Biologics include monoclonal antibodies, vaccines, cell therapies, gene therapies, and other biopharmaceuticals. Next-generation biomanufacturing technologies include advanced analytical tools, synthetic biology, genome editing, single-use systems, and process automation. These technologies aim to improve biomanufacturing processes' efficiency, scalability, and cost-effectiveness while maintaining high product quality and safety.
The research study on the next-generation biomanufacturing market overview thoroughly analyzes the market, along with the aspects that either help or hinder the market's growth, such as its drivers, challenges, and opportunities. The research also discusses the list of businesses that operate in this market and their efforts to establish themselves as major players through expansion plans and innovative ideas. It also emphasizes current events that support the market's revenue expansion. The research also analyses how the COVID-19 pandemic has affected society.
This report is an important tool for the industry stakeholders to gather all the information about the market, customers, and competition. The report also provides the readers with valuable insights on the segmentation, regions, market size & forecast, revenue CAGRs, and other valuable data to help make informed strategic decisions. The study compiles information gathered from industry participants and specialists across the industry value chain. The report also taps into the qualitative and quantitative assessments by industry analysts. Our reports use different methods for estimating the market size and forecast, including secondary research, surveys and interviews, and statistical modeling. With these steps, our reports provide the most accurate market data. These datasets will cumulatively provide in-depth next-generation biomanufacturing market forecast to the industry stakeholders.
[8657]
Next-Generation Biomanufacturing Market Dynamics
Biologics are complex molecules used to treat diseases such as cancer, autoimmune disorders, and infectious diseases. As the demand for these drugs continues to rise, the need for more efficient and cost-effective manufacturing processes has also increased, thus boosting the growth of the global next-generation biomanufacturing market. Additionally, there have been significant technological advancements in the biomanufacturing industry, such as using single-use systems, automation, and advanced analytics. These advancements have enabled biomanufacturers to produce biologics more efficiently, with higher yields and improved quality.
Additionally, high capital and operating costs, potential safety concerns, and competition from traditional manufacturing methods are some of the restraints impeding the overall next-generation biomanufacturing market growth.
Next-Generation Biomanufacturing Market Ecosystem
Next-Generation Biomanufacturing Market, by Workflow Type
Next-Generation Biomanufacturing Market, by Application
Next-Generation Biomanufacturing Market, by End User
Next-Generation Biomanufacturing Market by Application
[34867]
The monoclonal antibodies segment dominated the market with the largest revenue share in 2022, as they are widely used in treating cancer, autoimmune diseases, and other disorders. Monoclonal antibodies are proteins designed to bind to specific targets, such as cancer cells, and trigger an immune response that can help eliminate the target. Next-generation biomanufacturing technologies and processes can improve the efficiency and scalability of monoclonal antibody production while maintaining high product quality and safety.
Segmentation of the market refers to the division of the industry into subgroups based on factors such as workflow type, application, and end user. Market segmentation data helps businesses to understand the preferences and unique needs of different customer groups and develop targeted sales strategies. This information also helps in identifying potential next-generation biomanufacturing market growth opportunities.
Next-Generation Biomanufacturing Market by Region
North America dominated the global localized temperature therapy products market with the largest revenue share in 2022, owing to the presence of the world's leading biotechnology and pharmaceutical companies, research institutions, and regulatory agencies. The region has a strong infrastructure for biomanufacturing, including a skilled workforce, advanced facilities, and a favorable regulatory environment. In recent years, there has been significant investment in next-generation biomanufacturing in North America, particularly in the areas of cell and gene therapy, personalized medicine, and biologics manufacturing.
Based on the regions, the global next-generation biomanufacturing market is segmented into:
Regional demarcation of the industry will provide information on geographic pockets regarding next-generation biomanufacturing market outlook, size, share, and growth rate. This data helps businesses evaluate the expansion potential into new regional markets, understand the competitive threats across different regions, and develop localized sales and expansion strategies.
Key Components of the Report
Next-Generation Biomanufacturing Market Competitive Landscape
The market competitive landscape is performed by collecting and analyzing information about the key competitors, the present industry trends, and market dynamics. It includes information collection and analysis on factors such as products, pricing, geographic outreach, customer demographics, marketing strategies, and recent developments. Competitive landscape assessment will help businesses identify the current prevalent or potential opportunities and threats keeping in mind the next-generation biomanufacturing industry trends.
Next-Generation Biomanufacturing Market Strategic Developments
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Reasons to Buy this Report
Next-generation biomanufacturing is the application of advanced technologies and innovative processes to produce biologics, complex molecules produced by living cells that treat a wide range of diseases.
The global next-generation biomanufacturing market was valued at US$ 19.02 billion in 2022.
North American region will have the largest next-generation biomanufacturing market size during the forecast period from 2023 to 2031.
The revenue CAGR of the next-generation biomanufacturing market during the forecast period will be 6.9% from 2023 to 2031.
Increasing investment in biomanufacturing is the most prominent localized temperature therapy product trend.
The limited availability of effective treatments and the high cost of treatment are key challenges hampering the growth of the global next-generation biomanufacturing market.
Technological advances and increasing demand for biologics are growth opportunities in the next-generation biomanufacturing market.
Key players in the next-generation biomanufacturing market are Merck & Co., Meissner Filtration, ESCO Group LLC, Solaris Biotechnology, Applikon Biotechnology, GEA Group AG, and bbi-biotech GmbH.
The monoclonal antibodies application segment has the highest revenue share in the global next-generation biomanufacturing market.
*Insights on financial performance are subject to the availability of information in the public domain